JP2021521275A5 - - Google Patents

Info

Publication number
JP2021521275A5
JP2021521275A5 JP2021504593A JP2021504593A JP2021521275A5 JP 2021521275 A5 JP2021521275 A5 JP 2021521275A5 JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021521275 A5 JP2021521275 A5 JP 2021521275A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
binding protein
sequence shown
Prior art date
Application number
JP2021504593A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019198051A5 (https=
JP2021521275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/053040 external-priority patent/WO2019198051A2/en
Publication of JP2021521275A publication Critical patent/JP2021521275A/ja
Publication of JP2021521275A5 publication Critical patent/JP2021521275A5/ja
Publication of JPWO2019198051A5 publication Critical patent/JPWO2019198051A5/ja
Priority to JP2025006634A priority Critical patent/JP2025081307A/ja
Pending legal-status Critical Current

Links

JP2021504593A 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物 Pending JP2021521275A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006634A JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18167384 2018-04-13
EP18167385.6 2018-04-13
EP18167385 2018-04-13
EP18167384.9 2018-04-13
EP18190662.9 2018-08-24
EP18190662 2018-08-24
EP18190661.1 2018-08-24
EP18190661 2018-08-24
PCT/IB2019/053040 WO2019198051A2 (en) 2018-04-13 2019-04-12 Nk cell engaging antibody fusion constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006634A Division JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Publications (3)

Publication Number Publication Date
JP2021521275A JP2021521275A (ja) 2021-08-26
JP2021521275A5 true JP2021521275A5 (https=) 2022-04-20
JPWO2019198051A5 JPWO2019198051A5 (https=) 2022-04-20

Family

ID=66625219

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504593A Pending JP2021521275A (ja) 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Country Status (21)

Country Link
US (3) US11001633B2 (https=)
EP (1) EP3774914A2 (https=)
JP (2) JP2021521275A (https=)
KR (1) KR20200143436A (https=)
CN (3) CN113817066A (https=)
AU (2) AU2019252970A1 (https=)
BR (1) BR112020020828A2 (https=)
CA (1) CA3095373A1 (https=)
CL (2) CL2020002625A1 (https=)
CO (1) CO2020014167A2 (https=)
CR (1) CR20200549A (https=)
IL (1) IL277925A (https=)
MA (1) MA52227A (https=)
MX (1) MX2020010728A (https=)
PE (1) PE20201346A1 (https=)
PH (1) PH12020551664B1 (https=)
RU (1) RU2022105827A (https=)
SG (1) SG11202010064QA (https=)
TW (1) TW202012441A (https=)
WO (1) WO2019198051A2 (https=)
ZA (1) ZA202006325B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
EP4073117A1 (en) * 2019-12-10 2022-10-19 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
KR20220119467A (ko) 2019-12-27 2022-08-29 아피메트 게엠베하 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
US20230322953A1 (en) * 2020-06-30 2023-10-12 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
IL302402A (en) * 2020-11-08 2023-06-01 Seagen Inc Combined treatment
EP4255931A1 (en) * 2020-12-03 2023-10-11 Amgen Inc. Immunoglobuline constructs with multiple binding domains
WO2022161314A1 (zh) * 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
CA3233085A1 (en) * 2021-09-24 2023-03-30 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
JP2024543828A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
JP2025528087A (ja) * 2022-08-05 2025-08-26 チマゲン・バイオサイエンシズ，リミテッド 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体
JP2025531168A (ja) * 2022-09-14 2025-09-19 大塚製薬株式会社 Ｐｄ－１アゴニスト抗体
WO2024165028A1 (en) * 2023-02-06 2024-08-15 Concept To Medicine Biotech Co., Ltd. Anti-cd16a antibodies and uses thereof
WO2024186092A1 (ko) * 2023-03-06 2024-09-12 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2025257588A1 (en) * 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
PT2361936T (pt) * 2010-02-25 2016-07-15 Affimed Gmbh Molécula que se liga a antigénio e utilizações desta
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
ES2754557T3 (es) * 2015-05-04 2020-04-20 Affimed Gmbh Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
US10072088B2 (en) * 2015-08-17 2018-09-11 Janssen Pharmaceutica, Nv Anti-BCMA antibodies and uses thereof
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CA3051062C (en) * 2017-02-28 2023-09-26 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Similar Documents

Publication Publication Date Title
JP2021521275A5 (https=)
KR102607909B1 (ko) 항-cd28 조성물
RU2022105827A (ru) Слитые конструкции антител для вовлечения nk-клеток
JP7450684B2 (ja) 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
JPWO2019198051A5 (https=)
RU2767357C2 (ru) Биспецифические антитела-ингибиторы контрольных точек
JP2025061672A (ja) Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体
JP2018525382A5 (https=)
IL268836B1 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
JPWO2019226973A5 (https=)
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
US20250043001A1 (en) Anti-cd28 compositions
CN121311507A (zh) 抗cd28 x抗trop2抗体
JPWO2021170068A5 (https=)
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
US20250084186A1 (en) Anti-cd28 x anti-enpp3 antibodies
JPWO2023056252A5 (https=)
JPWO2022105817A5 (https=)
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
JPWO2021170071A5 (https=)
CN121311245A (zh) 用于治疗多发性骨髓瘤的方法
JP2026514025A (ja) 抗ｃｄ２８×抗ｅｎｐｐ３抗体
CA3212336A1 (en) Methods for treating multiple myeloma
WO2025090973A2 (en) Anti-trop2 x anti-pdl1 x anti-cd28 antibodies